Bayer HealthCare and OncoMed Pharmaceuticals Inc. are expanding their collaboration focusing on developing drugs that zero in on tumor-initiating cancer stem cells.
Bayer now will manufacture in its Berkeley facility the bulk drug substance for a drug that Redwood City-based OncoMed plans to take into a Phase I clinical trial in 2012.
No comments:
Post a Comment